Acquisition by Neha Krishnamohan of 215000 shares of Kinnate BiopharmaInc subject to Rule 16b-3
KNTEDelisted Stock | USD 2.96 0.27 8.36% |
About 61% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
Kinnate |
Filed transaction by Kinnate Biopharma Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Kinnate Biopharma Fundamental Analysis
We analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Kinnate Biopharma is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Kinnate Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kinnate Biopharma stock to make a market-neutral strategy. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics with similar companies.
Peers
Kinnate Biopharma Related Equities
SLRN | ACELYRIN, INC | 4.73 | ||||
GBIO | Generation Bio | 3.74 | ||||
PALI | Palisade Bio | 3.51 | ||||
KRON | Kronos Bio | 2.17 | ||||
BOLT | Bolt Biotherapeutics | 1.96 | ||||
ERAS | Erasca | 1.95 | ||||
PASG | Passage Bio | 1.54 | ||||
LRMR | Larimar Therapeutics | 1.00 | ||||
STOK | Stoke Therapeutics | 1.60 | ||||
GLUE | Monte Rosa | 2.22 | ||||
KROS | Keros Therapeutics | 2.32 | ||||
KZR | Kezar Life | 2.92 | ||||
EWTX | Edgewise Therapeutics | 3.10 | ||||
WINT | Windtree Therapeutics | 3.13 | ||||
DSGN | Design Therapeutics | 3.70 | ||||
IPSC | Century Therapeutics | 3.70 | ||||
CCCC | C4 Therapeutics | 5.25 | ||||
SRZN | Surrozen | 5.95 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |